Latest Articles
Researchers Investigate Non-Hormonal Alternatives for Uterine Fibroids and Endometriosis Affecting Up to 80% of Women - geneonline.com
Researchers Investigate Non-Hormonal Alternatives for Uterine Fibroids and Endometriosis Affecting Up to 80% of Women geneonline.com
Published: July 14, 2026, 7:41 a.m.
The One Vitamin Deficiency That May Increase Your Risk of Uterine Fibroids - Verywell Health
The One Vitamin Deficiency That May Increase Your Risk of Uterine Fibroids Verywell Health
Published: July 1, 2026, 12:22 p.m.
Kissei Pharmaceutical Aktie surges on Icelty launch for uterine fibroids in Japan - AD HOC NEWS
Kissei Pharmaceutical Aktie surges on Icelty launch for uterine fibroids in Japan AD HOC NEWS
Published: March 20, 2026, 5:40 a.m.
Louisiana lawmaker creates uterine fibroid commission to address women’s health gaps - KSLA
Louisiana lawmaker creates uterine fibroid commission to address women’s health gaps KSLA
Published: March 7, 2026, 12:42 a.m.
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment - The Malaysian Reserve
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment The Malaysian Reserve
Published: Oct. 8, 2025, 10:56 a.m.
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 - BMC Public Health
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 BMC Public Health
Published: May 14, 2025, 5:32 a.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - BioSpace
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids BioSpace
Published: May 7, 2025, 1:28 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times
Published: May 7, 2025, 12:24 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - PR Newswire
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids PR Newswire
Published: May 7, 2025, noon
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - 스페셜타임스
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids 스페셜타임스
Published: May 7, 2025, noon
Link copied to clipboard!